# LyGenesis doses first patient in Phase 2a trial growing ectopic livers in lymph nodes for end-stage liver disease

Canonical page: https://technooptimist.io/stories/lygenesis-doses-first-patient-in-phase-2a-trial-growing-ectopic-livers-4b897fed
Date: 2 Apr 2024
About: [LyGenesis](https://technooptimist.io/companies/lygenesis.md) · [LYG-LIV-001 ectopic liver](https://technooptimist.io/longevity/lyg-liv-001.md)
Original source: https://appliedclinicaltrialsonline.com/view/first-patient-dosed-in-phase-iia-trial-of-regenerative-cell-therapy-for-end-stage-liver-disease

LyGenesis dosed the first patient in an open-label, dose-escalation Phase 2a trial of LYG-LIV-001, donor liver cells injected into lymph nodes that act as living bioreactors to grow ectopic liver. The trial plans 12 patients with end-stage liver disease, each followed for over a year, with a safety board reviewing each cohort before the next, higher dose.

## Key facts

- Trial NCT04496479: open-label, dose-escalation, 12 planned patients.
- Cells come from donated livers that could not be matched for transplant.
- CEO Michael Hufford: one donated liver could treat many dozens of patients if it works.
- Investors include Juvenescence and Prime Movers Lab.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.